Elyse Watkins, DHSc, PA-C, DFAAPA
This article reviews the emerging literature on the efficacy of denosumab as a treatment for patients with Osteogenesis Imperfecta (OI). Denosumab improves bone density in adults with osteoporosis. There is a lack of evidence-based research to promote the use of denosumab as a current treatment in patients with OI. Denosumab research on bone density in OI patients is ongoing. The evidence suggests that denosumab use in OI patients does improve bone density but gives inconsistent results regarding fracture rate. Further research must establish the dosing and measurable gains of denosumab treatment in Osteogenesis Imperfecta.
Kopplin EL. Osteogenesis Imperfecta: A Review of Denosumab Research. Lynchburg Journal of Medical Science. 2020; 2(3).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.